"The IPO of Pershing Square Holdings is a transformational event for Pershing Square and all of our investors," CEO of PSCM, Bill Ackman said in a statement.
"We expect that the public listing of PSH will substantially enhance the stability of our capital base enabling us to invest a greater percentage of our assets in activist commitments on a long‐term basis, and improving our ability to take advantage of market dislocations when they arise," he said.
Read MoreAfter a rough year Bill Ackman is the comeback kid
Pershing Square will also invest $100 million itself in the fund, which will be separate from Ackman's $14 billion Pershing Square Capital Management.
The firm said it expected the new fund to have a market capitalization of at least $5 billion on completion of the initial public offering. UBS and the London branch of Deutsche Bank will act as joint global co-ordinators and joint underwriters.
Known for his $1 billion bet against health shake company Herbalife, Ackman has recently teamed up with Valeant Pharmaceuticals to pursue a hostile takeover bid for botox maker Allergan.
Activist hedge fund strategies, run by the likes of Ackman and rival Carl Icahn, have become increasingly popular. Investors have poured in over $18 billion since the start of 2013, bringing the asset base growth of these strategies to over $30 billion when performance is included, according to figures from hedge fund data provider Eurekahedge.
—By CNBC's Jenny Cosgrave: Follow her on Twitter @jenny_cosgrave